Member Info for AquaeSulis01

Testing not harvesting Danny interpretive text

Travel. I have not said harvesting is not a key part of the solution, but that testing alone will not suddenly lead to freedom of travel without the fear of a Country seeing spikes and hence added to being added to a blacklist. No country in the world was and is better prepared for test in than South Korea and yet they are now experiencing a second wave. https://uk.reuters.com/article/us-health-coronavirus-southkorea/south-korea-warns-of-nationwide-coronavirus-spread-as-church-outbreaks-threaten-capital-idUKKCN25F05N

If you think testing alone will kick start international travel and cruising then you are sadly deluded. If your cruise ship with all your covid 19 tested clear passengers docks in India, what are your levels of confidence that the population there has been accurately tested?

There are over 100 covid19 vaccines in development, 20 of which are front runners. Open Urphan are working on an attenuated version of the virus so that the most promising vaccines can be tested under accelerated conditions through deliberately infecting volunteers post vaccination. See attached at 7 minutes 32 seconds through to 9 minutes 45 seconds

https://www.sharesmagazine.co.uk/video/open-orphan-orph-cathal-friel-executive-chairman-3

First time that Hurricane (via its mouthpiece Edison) has admitted that 7z is likely from the aquifer. Well as has been said previously, the last Edison report was bullish and totally wrong, so hopefully for you LTH's, this bearish report proves equally wrong

In our previous note we outlined a number of remedial options to bring the 205/21a-7z well back
into production. Hurricane has since commissioned the ESPs in both wells and, prior to the recent
shutdown, the 7z well was producing using an ESP at a rate of c 5,000bod and a water-cut of 53%,
while the 205/21a-6 well was flowing naturally at c 12,000bod and a water cut of c 12%. We note
Hurricane Energy | 18 August 2020 3
that the six well sits around 20m higher than the 7z well, so that water influx here can be expected
to lag behind that seen in 7z (assuming that water production could be coming from the aquifer
rather than being ‘perched water’ as had initially been assumed).

Podcast to go with the RNS

https://twitter.com/PowerMetRes/status/1295330962830766081?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet

Moniman, you are correct in that a company would normally report Contract news that it does not expect to have a material affect on the sp as a RNS REACH. It would therefore suggest that Cathal felt the contracts would have a material affect on the sp (in fact they did temporarily until sold into on each occasion). He has also made it as clear as possible in a series of interviews that the company will be unrecognisable by Christmas and is already profitable, so is anyone not looking forward to the half year report when the cumulative financial impact of all these contracts will be revealed?

Agree Jomzi, and likewise although it was a struggle to buy

On the testing front. not sure it is right to assume that testing didn't take off Hvivo. At 24:50 on the attached video, Cathal mentions that OO offer PCRI and Antibody testing to large companies and that it is a "nice steady growing business". Also, once the Covid vaccines are tested by OO and they buikd up the data form the various vaccine tests, crucial information will emerge re the specific and type of antibodies that provide protection from the virus. i suspect at that point, the real usefulness of a sophisticated antibody testing machine to ensure individuals in the workplace really are immune, will really come to the fore. On a separate note, at 24:30 on the presentation, Cathal now confirms OO are profitable so as we are still less than eight months through the year, that sounds pretty amazing to me

https://www.sharesmagazine.co.uk/video/open-orphan-orph-cathal-friel-executive-chairman-3

Days have flown by and we have already had three new contract wins

Lucky, perhaps you ought to check your own facts first. The two contracts, including the £4M contract are not one of the 10 covid challenge trials whick will attract circa £10M a piece

Moniman, agree with you re pointless ramping but disagree that OO has not demonstrated to the market that they are moving into profit. RNS Contract news since the loss making end Dec19 Results are as follows:
RNS Number : 7544Y 06 January 2020
3 Year Contract with major Pharmaceutical Company
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a new 3-year contract with a tier 1 German pharmaceutical company which is one of Europe's top research-driven pharmaceutical companies. The contract guarantees significant annual revenue with work under the contract to commence this month.
Fri, 6th Mar 2020 07:00
RNS Number : 2129F
New hVIVO contract signed with a European Biotech Company Projected to deliver £3.2m in revenue in 2020 with the pivotal challenge study expected to commence end Q4 2020, with the potential to deliver significant further revenue expected to be a minimum of £7m.
Thu, 23rd Apr 2020 07:00
RNS Number : 5708K
Testing of anti-viral for treating COVID-19 underway
Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that its London-based subsidiary hVIVO has commenced the testing of an anti-viral for treating COVID-19 on behalf of its client Nearmedic International Ltd.
Mon, 4th May 2020 07:00
RNS Number : 7378L
Major New Contract and Directorate Change
New contract signed with US Biotechnology Company for respiratory syncytial virus (RSV) human challenge study
Challenge study projected to deliver £3.5 million in revenue in 2020
Thu, 11th Jun 2020 07:00
Pleased to announce that it has signed a major contract with a leading vaccine developer and one of the top pharmaceutical companies in the world. The contract with Venn Life Sciences, which is part of Open Orphan, builds on earlier successful contracts between the companies and is to obtain and support market access of newly developed vaccines into the EU and US markets until the end of 2020.
Tue, 28th Jul 2020 07:00
RNS Number : 2256U
Open Orphan PLC
28 July 2020

Awarded Contract from Codagenix Inc. New York USA for COVID-19 Vaccine Trial
Pleased to announce a new contract with Codagenix Inc. ("Codagenix") to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers
Tue, 4th Aug 2020 07:00
RNS Number : 0001V
New Contract Win with Carna Bioscience Carna Bioscience (www.carnabio.com) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for Venn Life Sciences ("Venn") over the next twelve months.
RNS Number : 5695V
10 August 2020
Major New Contract Win with Top 3 Pharma Company a new contract, valued at £4m,

If you listen to the podcast at the linl provided by Trek you are told the top 3 are Novartis, Pfizer and J&J so perm two from those three

Moaning man, you never disappoint, thought even you might be mildly content with the blue finish; certainly keeping us all grounded. This is my largest holding, I have bought and held, and my eyes remain firmly on the Imutex prize, the RNS for which could land anytime between now and Christmas

Great research deepjoy, and thanks. Will be interesting tracking the sp post the 15th Aug

Midday Bath on Wednesday, Burger, chips and beer £5 reduced from £10, utilising Government scheme, and a 10 minute queue to get seating

precedent not president !

Worth adding that the president was set for a company dumping their shares for less than the company was worth when the share price here languished around 5p and promptly doubled to their true worth once the large seller was through.

Moniman, I was trying to answer your specific question re MMs and in this case explain the hasty sell of OO shares linked to an imposed timeline. I am not ramping this share, but at the end of the day if you do not believe in the Board then you best sell and move on, personally, I see an enthusiastic leader in Cathal, fully invested and delivering on his promises.

Moniman. MMs earn most of their money through the difference in the spread irrespective of the share price itself along with a commission from their clients. In this case, Acacia are working to a time based deadline to sell the stock s by 30th Nov so that finds can be returned to Woodford find investors. The documents seen by Citywire show investors in the Woodford fund face further delays in receiving money. Both buyer and seller are reportedly working towards a deadline of 30 November but they can agree to a one-month extension. It means investors frozen in the fund could be waiting until Christmas before receiving the proceeds.://www.cityam.com/acacia-research-offloads-bargain-woodford-stocks/